Complete Filing Data
bioAffinity Technologies, Inc. reported Stockholders Equity of $7.28 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean bioAffinity Technologies, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income Loss | -$14.9M | -$9.0M | -$7.9M | -$8.2M | -$6.3M |
| Research And Development Expense | $1.4M | $1.5M | $1.5M | $1.4M | $1.0M |
| Operating Income Loss | -$10.6M | -$9.0M | -$8.0M | -$4.0M | -$2.2M |
| Operating Expenses | $16.7M | $18.3M | $10.5M | $4.0M | $2.2M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$14.9M | -$9.0M | -$7.9M | -$8.2M | -$6.3M |
| Income Tax Expense Benefit | $44.0K | $11.7K | $21.0K | $2.5K | $2.0K |
| Selling General And Administrative Expense | $9.9M | $9.9M | $6.8M | $2.5M | $1.1M |
| Revenue From Contract With Customer Excluding Assessed Tax | $6.2M | $9.4M | $2.5M | $4.8K | |
| Income Taxes Paid Net | $23.4K | $17.6K | $21.0K | $30.6K | $2.0K |
| Interest Expense Nonoperating | $44.4K | $92.5K | $37.1K | ||
| Other Nonoperating Income | $40.5K | $10.3K | $3.3K | ||
| Nonoperating Income Expense | |||||
| Other Nonoperating Expense | $502.4K | $10.2K | $31.1K | ||
| Deferred Revenue Current | $42.4K | $24.4K | $33.1K | ||
| Interest Expense | $37.1K | $2.5M | $1.0M | ||
| Cost Of Revenue | $467.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Loss | -$5.1M | -$4.1M | -$2.7M | -$2.0M | -$2.1M | -$2.0M | -$2.3M | -$1.7M | -$1.5M | -$4.9M | -$88.1K | -$1.5M | -$1.5M |
| Research And Development Expense | $330.6K | $311.4K | $367.4K | $274.5K | $402.4K | $393.6K | $330.4K | $335.1K | $369.6K | $319.7K | $248.4K | $279.8K | $330.8K |
| Operating Income Loss | -$2.3M | -$2.5M | -$2.6M | -$2.0M | -$2.1M | -$1.9M | -$2.3M | -$1.8M | -$1.6M | -$976.2K | -$684.1K | -$727.0K | -$526.3K |
| Operating Expenses | $3.7M | $3.8M | $4.5M | $4.3M | $4.5M | $4.4M | $2.6M | $1.8M | $1.6M | $977.2K | $685.3K | $727.0K | $526.3K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$5.0M | -$4.0M | -$2.7M | -$2.0M | -$2.1M | -$2.0M | -$2.3M | -$1.7M | -$1.5M | -$4.9M | -$88.1K | -$1.5M | -$1.5M |
| Income Tax Expense Benefit | $3.2K | $29.0K | $8.7K | $2.6K | $5.4K | $3.7K | $2.3K | $4.6K | $11.8K | $300.00 | $2.2K | ||
| Selling General And Administrative Expense | $2.2M | $2.2M | $2.5M | $2.4M | $2.5M | $2.2M | $2.0M | $1.4M | $1.1M | $595.7K | $408.6K | $394.7K | |
| Revenue From Contract With Customer Excluding Assessed Tax | $1.4M | $1.3M | $1.9M | $2.4M | $2.4M | $2.4M | $298.5K | $19.7K | $921.00 | $1.2K | $1.3K | ||
| Income Taxes Paid Net | $8.7K | $3.7K | $1.7K | $2.2K | |||||||||
| Interest Expense Nonoperating | $5.4K | $10.5K | $15.5K | $21.6K | $22.2K | $23.6K | $8.8K | $1.4K | |||||
| Other Nonoperating Income | $513.00 | $38.1K | $2.00 | $9.7K | $1.00 | $4.5K | $4.6K | ||||||
| Nonoperating Income Expense | -$2.8M | -$1.5M | -$24.6K | -$24.4K | -$17.1K | -$12.9K | $5.9K | $42.8K | $37.0K | -$1.1M | |||
| Other Nonoperating Expense | $3.8K | $483.0K | $9.6K | $14.7K | $17.1K | ||||||||
| Deferred Revenue Current | $37.9K | $24.4K | $24.4K | $24.4K | $26.1K | $30.2K | $38.3K | $42.8K | |||||
| Interest Expense | $23.6K | $8.8K | $1.4K | $1.7K | $896.5K | $399.3K | $135.4K | ||||||
| Cost Of Revenue | $74.7K | $1.2K | $87.00 | $146.00 | $146.00 |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Stockholders Equity | $7.3M | $2.6M | $4.9M | $11.0M | -$15.8M | -$15.1M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $6.4M | $1.1M | $2.8M | $11.4M | $1.4M | $83.1K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $5.3M | -$1.7M | -$8.6M | $10.1M | $1.3M | |
| Common Stock Value | $31.5K | $3.6K | $65.8K | $58.7K | $18.7K | |
| Retained Earnings Accumulated Deficit | -$68.6M | -$53.6M | -$44.6M | -$36.7M | -$28.5M | |
| Property Plant And Equipment Net | $265.6K | $375.4K | $458.6K | $214.4K | $4.6K | |
| Prepaid Expense And Other Assets Current | $519.9K | $423.0K | $321.0K | $531.9K | $76.1K | |
| Other Assets Noncurrent | $12.8K | $19.7K | $16.1K | $6.0K | $2.5K | |
| Liabilities Current | $2.9M | $3.1M | $2.2M | $1.1M | $13.0M | |
| Liabilities And Stockholders Equity | $11.0M | $6.5M | $8.2M | $12.2M | $1.5M | |
| Liabilities | $3.7M | $3.9M | $3.4M | $1.1M | $13.2M | |
| Cash And Cash Equivalents At Carrying Value | $6.4M | $1.1M | $2.8M | $11.4M | $1.4M | |
| Assets Current | $7.6M | $2.7M | $4.0M | $12.0M | $1.4M | |
| Assets | $11.0M | $6.5M | $8.2M | $12.2M | $1.5M | |
| Accrued Liabilities Current | $1.7M | $1.4M | $1.1M | $541.9K | $483.5K | |
| Accounts Payable Current | $761.9K | $987.3K | $604.8K | $345.0K | $230.4K | |
| Accounts And Other Receivables Net Current | $542.0K | $1.1M | $811.7K | $10.5K | $1.5K | |
| Inventory Net | $53.5K | $27.6K | $18.5K | $5.5K | ||
| Finance Lease Principal Payments | $324.3K | $361.2K | $93.2K | |||
| Operating Lease Right Of Use Asset | $334.3K | $463.0K | $370.3K | |||
| Operating Lease Liability Noncurrent | $202.9K | $342.1K | $283.0K | |||
| Operating Lease Liability Current | $139.2K | $127.5K | $94.7K | |||
| Intangible Assets Net Excluding Goodwill | $716.8K | $775.1K | $833.5K | |||
| Goodwill | $1.4M | $1.4M | $1.4M | |||
| Finance Lease Liability Noncurrent | $532.8K | $444.4K | $835.5K | |||
| Finance Lease Liability Current | $139.5K | $395.3K | $365.5K | |||
| Finance Lease Right Of Use Asset | $661.6K | $780.9K | $1.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $8.9M | -$2.1M | $1.4M | $3.1M | $3.4M | $5.3M | $7.0M | $8.1M | $9.7M | $12.6M | -$16.8M | -$16.7M | -$15.7M | -$14.2M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $7.7M | $802.8K | $444.7K | $756.6K | $801.3K | $2.5M | $4.5M | $8.3M | $9.8M | $13.5M | $214.4K | $1.0M | $243.8K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$660.6K | -$368.4K | -$1.6M | -$332.6K | ||||||||||
| Common Stock Value | $24.3K | $197.2K | $124.8K | $90.1K | $79.4K | $78.5K | $64.5K | $59.9K | $59.2K | $58.6K | ||||
| Retained Earnings Accumulated Deficit | -$65.4M | -$60.4M | -$56.3M | -$50.7M | -$48.7M | -$46.6M | -$42.2M | -$39.9M | -$38.2M | -$35.0M | ||||
| Property Plant And Equipment Net | $303.1K | $351.4K | $382.4K | $418.2K | $449.3K | $461.2K | $512.2K | $207.4K | $225.1K | $1.8K | ||||
| Prepaid Expense And Other Assets Current | $460.2K | $400.2K | $416.6K | $440.0K | $253.7K | $344.9K | $382.7K | $279.7K | $441.1K | $541.3K | ||||
| Other Assets Noncurrent | $12.8K | $12.8K | $19.7K | $19.7K | $19.7K | $16.1K | $16.1K | $6.9K | $6.9K | $6.0K | ||||
| Liabilities Current | $2.4M | $2.6M | $3.4M | $2.5M | $2.3M | $1.8M | $2.0M | $775.2K | $796.3K | $1.5M | ||||
| Liabilities And Stockholders Equity | $11.5M | $4.8M | $5.5M | $6.6M | $6.7M | $8.0M | $10.2M | $8.9M | $10.5M | $14.1M | ||||
| Liabilities | $2.6M | $6.9M | $4.1M | $3.4M | $3.2M | $2.8M | $3.2M | $775.2K | $796.3K | $1.5M | ||||
| Cash And Cash Equivalents At Carrying Value | $7.7M | $802.8K | $444.7K | $756.6K | $801.3K | $2.5M | $4.5M | $8.3M | $9.8M | $13.5M | ||||
| Assets Current | $8.6M | $1.7M | $1.9M | $2.5M | $2.7M | $3.9M | $6.0M | $8.7M | $10.2M | $14.1M | ||||
| Assets | $11.5M | $4.8M | $5.5M | $6.6M | $6.7M | $8.0M | $10.2M | $8.9M | $10.5M | $14.1M | ||||
| Accrued Liabilities Current | $984.5K | $1.0M | $1.4M | $904.3K | $969.1K | $883.3K | $643.8K | $515.7K | $481.3K | $474.0K | ||||
| Accounts Payable Current | $940.8K | $1.2M | $1.4M | $782.9K | $848.1K | $384.0K | $827.4K | $174.4K | $146.5K | $149.9K | ||||
| Accounts And Other Receivables Net Current | $449.0K | $421.9K | $963.7K | $1.3M | $1.6M | $1.1M | $1.1M | $90.2K | $11.0K | $9.9K | ||||
| Inventory Net | $35.2K | $44.0K | $38.8K | $25.4K | $29.8K | $9.5K | $9.9K | $10.1K | $11.3K | $5.7K | ||||
| Finance Lease Principal Payments | $58.0K | $93.0K | $100.3K | $91.0K | $90.4K | $88.7K | ||||||||
| Operating Lease Right Of Use Asset | $367.4K | $399.9K | $431.7K | $493.7K | $324.9K | $347.9K | $392.3K | |||||||
| Operating Lease Liability Noncurrent | $238.9K | $274.1K | $308.4K | $375.1K | $232.7K | $258.1K | $307.4K | |||||||
| Operating Lease Liability Current | $136.2K | $133.2K | $130.3K | $124.7K | $98.6K | $96.6K | $90.9K | |||||||
| Intangible Assets Net Excluding Goodwill | $731.4K | $746.0K | $760.6K | $789.7K | $804.3K | $818.9K | $848.1K | |||||||
| Goodwill | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M | $1.1M | |||||||
| Finance Lease Liability Noncurrent | $2.0K | $3.9K | $335.9K | $543.0K | $641.6K | $739.5K | $929.6K | |||||||
| Finance Lease Liability Current | $123.8K | $179.8K | $403.6K | $387.8K | $380.3K | $372.8K | $358.3K | |||||||
| Finance Lease Right Of Use Asset | $113.6K | $167.7K | $684.6K | $877.1K | $973.4K | $1.1M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Stock Issued During Period Value Share Based Compensation | $671.5K | $989.7K | $748.8K | $248.6K | $43.0K |
| Share Based Compensation | $671.5K | $989.7K | $748.8K | $248.6K | $43.0K |
| Net Cash Provided By Used In Operating Activities | -$9.3M | -$7.3M | -$6.0M | -$4.1M | -$2.0M |
| Net Cash Provided By Used In Financing Activities | $14.7M | $5.6M | -$345.0K | $14.3M | $3.3M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $90.1K | $105.6K | -$214.4K | $492.8K | $35.0K |
| Increase Decrease In Accrued Liabilities | $319.3K | $248.9K | $362.0K | $66.3K | $107.7K |
| Increase Decrease In Accounts Payable | -$225.4K | $382.5K | -$14.5K | $114.6K | $39.0K |
| Increase Decrease In Inventories | $25.9K | $9.1K | $12.9K | $5.5K | |
| Increase Decrease In Accounts And Other Receivables | -$597.2K | $327.5K | -$311.4K | $9.0K | |
| Payments To Acquire Property Plant And Equipment | $60.6K | $79.1K | $22.9K | $220.0K | |
| Net Cash Provided By Used In Investing Activities | -$60.6K | -$79.1K | -$2.2M | -$220.0K | |
| Increase Decrease In Operating Lease Right Of Use Asset | -$1.2K | $812.00 | -$7.4K | ||
| Increase Decrease In Deferred Revenue | $18.0K | -$8.7K | $33.1K | ||
| Proceeds From Issuance Initial Public Offering | $11.1M | $5.6M | $6.0M | ||
| Payments Of Stock Issuance Costs | $1.8M | $1.3M | $1.8M | ||
| Proceeds From Warrant Exercises | $4.8M | $1.4M | $7.7M | ||
| Proceeds From Stock Options Exercised | $74.9K | $74.9K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value Share Based Compensation | $67.1K | $211.6K | $326.6K | $185.7K | $286.2K | $283.7K | $186.4K | $170.3K | $157.6K | $79.0K | $26.7K | $106.0K | -$20.3K |
| Share Based Compensation | $326.6K | $283.7K | $157.6K | $106.0K | |||||||||
| Net Cash Provided By Used In Operating Activities | -$1.6M | -$2.3M | -$1.5M | -$634.0K | |||||||||
| Net Cash Provided By Used In Financing Activities | $1.0M | $2.0M | -$83.3K | $301.4K | |||||||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$6.4K | $23.9K | -$89.8K | -$11.1K | |||||||||
| Increase Decrease In Accrued Liabilities | -$28.0K | -$266.5K | -$60.6K | -$29.6K | |||||||||
| Increase Decrease In Accounts Payable | $394.3K | -$220.8K | -$198.5K | $17.3K | |||||||||
| Increase Decrease In Inventories | $11.2K | -$9.0K | $5.8K | $5.8K | |||||||||
| Increase Decrease In Accounts And Other Receivables | -$175.5K | $311.9K | $538.00 | $5.3K | |||||||||
| Payments To Acquire Property Plant And Equipment | $50.8K | $41.4K | $32.3K | ||||||||||
| Net Cash Provided By Used In Investing Activities | -$50.8K | -$41.4K | -$32.3K | ||||||||||
| Increase Decrease In Operating Lease Right Of Use Asset | -$426.00 | $516.00 | |||||||||||
| Increase Decrease In Deferred Revenue | -$2.9K | ||||||||||||
| Proceeds From Issuance Initial Public Offering | $3.3M | $2.0M | |||||||||||
| Payments Of Stock Issuance Costs | $495.0K | $1.8M | |||||||||||
| Proceeds From Warrant Exercises | $1.2M | ||||||||||||
| Proceeds From Stock Options Exercised | $74.9K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 1.7M | 404.2K | 8.7M | 4.5M | 2.7M |
| Earnings Per Share Basic | $-8.66 | $-22.50 | $-0.91 | $-1.81 | $-2.36 |
| Common Stock Shares Authorized | 350.0M | 350.0M | 100.0M | 14.3M | 14.3M |
| Weighted Average Number Of Diluted Shares Outstanding | 1.7M | 404.2K | 8.7M | 4.5M | |
| Earnings Per Share Diluted | $-8.66 | $-22.50 | $-0.91 | $-1.81 | |
| Common Stock Par Or Stated Value Per Share | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 |
| Common Stock Shares Issued | 4.5M | 519.2K | 9.4M | 8.4M | 2.7M |
| Common Stock Shares Outstanding | 4.5M | 519.2K | 9.4M | 8.4M | 2.7M |
| Preferred Stock Shares Outstanding | 700.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Issued | 700.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Authorized | 20.0M | 20.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 1.1M | 24.0M | 16.3M | 412.9K | 11.4M | 9.9M | 8.7M | 8.5M | 8.4M | 4.2M | 2.7M | 2.7M | 2.7M | ||
| Earnings Per Share Basic | $-4.74 | $-0.17 | $-0.16 | $-4.84 | $-0.19 | $-0.20 | $-0.26 | $-0.20 | $-0.18 | $-1.17 | $-0.03 | $-0.55 | $-0.57 | ||
| Common Stock Shares Authorized | 350.0M | 100.0M | 100.0M | 100.0M | 100.0M | 25.0M | 25.0M | 25.0M | 14.3M | 14.3M | |||||
| Weighted Average Number Of Diluted Shares Outstanding | 1.1M | 24.0M | 16.3M | 412.9K | 11.4M | 9.9M | 8.7M | 8.5M | 8.4M | 4.2M | 2.7M | ||||
| Earnings Per Share Diluted | $-4.74 | $-0.17 | $-0.16 | $-4.84 | $-0.19 | $-0.20 | $-0.26 | $-0.20 | $-0.18 | $-1.17 | $-0.03 | ||||
| Common Stock Par Or Stated Value Per Share | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | ||||
| Common Stock Shares Issued | 3.5M | 28.5M | 18.3M | 13.4M | 11.5M | 11.2M | 9.2M | 8.6M | 8.5M | 8.4M | |||||
| Common Stock Shares Outstanding | 3.5M | 28.5M | 18.3M | 13.4M | 11.5M | 11.2M | 9.2M | 8.6M | 8.5M | 8.4M | |||||
| Preferred Stock Shares Outstanding | 700.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
| Preferred Stock Shares Issued | 700.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 20.0M | 20.0M | 20.0M | 20.0M | 20.0M | 20.0M | 20.0M | 20.0M | 20.0M | 20.0M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Clinical Development Expense | $705.7K | $321.7K | $256.7K | $145.5K | $130.5K |
| Investment Income Interest | $23.4K | $17.6K | $122.1K | $46.7K | $424.00 |
| Depreciation And Amortization | $504.8K | $605.6K | $249.6K | $10.2K | $4.8K |
| Direct Costs And Expenses | $4.2M | $6.0M | $1.7M | $467.00 | |
| Additional Paid In Capital | $75.8M | $56.2M | $49.4M | $47.7M | $12.7M |
| Interest Paid Net | $44.0K | $11.7K | $37.1K | $2.5K | |
| Stock Issued During Period Value Warrants Exercised | $4.8M | $1.4M | $7.7M | ||
| Stock Issued During Period Value Other | $8.1M | $5.6M | $16.1M | ||
| Stock Issued During Period Value Stock Options Exercised | $74.9K | $74.9K | |||
| Adjustments To Additional Paid In Capital Stock Issued Issuance Costs | $1.8M | $1.3M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Development Expense | $143.3K | $129.3K | $138.4K | $93.7K | $51.5K | $49.0K | $106.4K | $35.3K | $19.6K | $60.9K | $28.2K | $52.5K | $34.0K |
| Investment Income Interest | $1.1K | $2.0K | $542.00 | $2.2K | $5.2K | $6.1K | $27.2K | $44.1K | $38.7K | $7.4K | $276.00 | $19.00 | |
| Depreciation And Amortization | $113.4K | $113.2K | $154.6K | $151.3K | $151.1K | $149.6K | $57.6K | $21.6K | $21.7K | $773.00 | $1.0K | ||
| Direct Costs And Expenses | $942.2K | $1.0M | $1.4M | $1.4M | $1.4M | $1.6M | $74.7K | $1.2K | $87.00 | ||||
| Additional Paid In Capital | $74.3M | $58.0M | $57.6M | $53.7M | $52.0M | $51.7M | $49.2M | $48.0M | $47.8M | $47.5M | |||
| Interest Paid Net | $542.00 | $23.6K | $11.8K | ||||||||||
| Stock Issued During Period Value Warrants Exercised | $5.6M | $40.1K | $1.5M | $1.3M | $147.00 | $7.7M | |||||||
| Stock Issued During Period Value Other | $6.1M | $242.3K | $450.0K | $2.5M | $16.1M | ||||||||
| Stock Issued During Period Value Stock Options Exercised | $74.9K | $74.9K | |||||||||||
| Adjustments To Additional Paid In Capital Stock Issued Issuance Costs | $1.1M | $8.8K | $347.3K | $290.2K | $495.0K |
Most recent annual filing with the SEC: March 16, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.